Multicenter, Randomized, Phase III, Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia
Latest Information Update: 26 Aug 2024
At a glance
- Drugs Meningococcal vaccine group B OMV Novartis (Primary) ; PF 5212366 (Primary)
- Indications Meningococcal group B infections
- Focus Pharmacodynamics
- Acronyms SPLEMENGO
Most Recent Events
- 10 Oct 2022 Planned End Date changed from 1 Aug 2028 to 1 Oct 2028.
- 10 Oct 2022 Planned primary completion date changed from 1 Jul 2028 to 1 Sep 2028.
- 10 Oct 2022 Status changed from not yet recruiting to recruiting.